Tipranavir-d4 is intended for use as an internal standard for the quantification of tipranavir by GC- or LC-MS. Tipranavir is a potent, orally bioavailable nonpeptidic HIV aspartyl protease inhibitor (Ki = <1 nM) that prevents cleavage and thus activation of functional HIV-cleaved proteins.1,2 Formulations containing tipranavir, in combination with other HIV treatments, are effective against multidrug resistant viruses and are used in the treatment of HIV infection progression in patients who have not responded well to initial treatments.
|1. Thaisrivongs, S., and Strohbach, J.W. Structure-based discovery of Tipranavir disodium (PNU-140690E): A potent, orally bioavailable, nonpeptidic HIV protease inhibitor. Biopoly. 51(1), 51-58 (1999).|2. Turner, S.R., Strohbach, J.W., Tommasi, R.A., et al. Tipranavir (PNU-140690): A potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide class. J. Med. Chem. 41(18), 3467-3476 (1998).